These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28595133)

  • 1. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
    Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
    Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
    Juul RV; Rasmussen MH; Agersø H; Overgaard RV
    Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
    Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
    Kildemoes RJ; Hollensen C; Biller BMK; Johannsson G; Takahashi Y; Rasmussen MH
    Eur J Endocrinol; 2022 May; 187(1):27-38. PubMed ID: 35521713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
    Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
    Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
    Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.
    Johannsson G; Feldt-Rasmussen U; Håkonsson IH; Biering H; Rodien P; Tahara S; Toogood A; Rasmussen MH;
    Eur J Endocrinol; 2018 May; 178(5):491-499. PubMed ID: 29500310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.
    Otsuka F; Takahashi Y; Tahara S; Ogawa Y; Højby Rasmussen M; Takano K
    Clin Endocrinol (Oxf); 2020 Nov; 93(5):620-628. PubMed ID: 32603494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects.
    Helleberg H; Bjelke M; Damholt BB; Pedersen PJ; Rasmussen MH
    Eur J Pharm Sci; 2021 Dec; 167():106030. PubMed ID: 34601071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
    Juul Kildemoes R; Højby Rasmussen M; Agersø H; Overgaard RV
    J Clin Endocrinol Metab; 2021 Jan; 106(2):567-576. PubMed ID: 33313798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats.
    Helleberg H; Lindecrona RH; Thygesen P; Bjelke M
    Eur J Pharm Sci; 2022 Jan; 168():106032. PubMed ID: 34610450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency.
    Kildemoes RJ; Backeljauw PF; Højby M; Blair JC; Miller BS; Mori J; Lyauk YK
    J Endocr Soc; 2023 Oct; 7(11):bvad115. PubMed ID: 37818403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
    Osborn BL; Sekut L; Corcoran M; Poortman C; Sturm B; Chen G; Mather D; Lin HL; Parry TJ
    Eur J Pharmacol; 2002 Dec; 456(1-3):149-58. PubMed ID: 12450581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.
    Ashkenazi N; Rosenstock M; Hallak H; Bassan M; Rasamoelisolo M; Leuschner J; Shinar D
    Growth Horm IGF Res; 2016; 30-31():16-21. PubMed ID: 27552669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.
    Mori J; Ohata Y; Fujisawa Y; Sato Y; Röhrich S; Rasmussen MH; Bang RB; Horikawa R
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):389-398. PubMed ID: 38368603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
    Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3378-3388. PubMed ID: 36062966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial.
    Dombernowsky SL; Damholt BB; Højby Rasmussen M; Sværke C; Kildemoes RJ
    Clin Pharmacokinet; 2024 Jul; 63(7):1015-1024. PubMed ID: 38969919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.